-
UPDATE: Citigroup Reiterates Sell Rating, Lowers PT for St. Jude Medical
Monday, May 14, 2012 - 11:51am | 168In a company update published earlier today, Citigroup Inc. reiterated its Sell rating for St. Jude Medical, Inc. (NYSE: STJ) and slightly lowered its price target from $37.00 to $36.00. Citigroup said it made its decisions “reflective of the company's current valuation combined with difficult...
-
UPDATE: Citigroup Maintains Buy Rating, Lowers PT for Medtronic
Monday, May 14, 2012 - 11:39am | 133In a company update published earlier today, Citigroup Inc. maintained its Buy rating for Medtronic, Inc. (NYSE: MDT) and slightly lowered its price target from $48.00 to $47.00. Citigroup went on to say “Medtronic's relative price-to-earnings (P/E) multiple to its large-cap med tech peers is at a...
-
UPDATE: Citigroup Reiterates Neutral Rating, Raises PT for Boston Scientific
Monday, May 14, 2012 - 11:33am | 161In a company update published earlier today, Citigroup Inc. reiterated its Neutral rating for the Boston Scientific Corporation (NYSE: BSX) and slightly raised its price target from $6.30 to $6.50. Citigroup went on to say “In March 2004, Boston Scientific entered an unprecedented new product...
-
UPDATE: Citigroup Reiterates Buy Rating, Raises PT for hiSoft Technology
Friday, May 11, 2012 - 10:07am | 108In a company update published earlier today, Citigroup Inc. reiterated its Buy rating for hiSoft Technology International Limited (NASDAQ: HSFT) and raised its price target from $18.00 to $20.00. Citigroup went on to say “1Q shows an improving margin and growth in high valued-added segments. 2012-...
-
UPDATE: Citigroup Reiterates Neutral Rating, Raises PT for DigitalGlobe
Wednesday, May 2, 2012 - 1:04pm | 172In a company update released earlier today, Citigroup Inc. reiterated its Neutral rating for DigitalGlobe, Inc. (NYSE: DGI) and slightly raised its price target from $14.75 to $15.00. Citigroup went on to say “1Q12 failed to fully address our looming concerns over DGI's largest program,...
-
Citigroup Maintains Buy Rating, $85 PT for Watson Pharmaceuticals
Monday, April 30, 2012 - 12:47pm | 159In a company update issued earlier today, Citigroup Inc. maintained its Buy rating and $85.00 price target for Watson Pharmaceuticals, Inc. (NYSE: WPI). Citigroup said it made its decisions “assuming the company trades at a forward P/E multiple of ~10x our 2013E NEWCO cash EPS estimate of $8.49,...
-
UPDATE: Citigroup Maintains Buy Rating, Raises PT for KBR
Friday, April 27, 2012 - 11:23am | 126In a company update published earlier today, Citigroup Inc. maintained its Buy rating for KBR, Inc. (NYSE: KBR) and slightly raised its price target from $50.00 to $51.00. Citigroup said “In our view, further upside is likely and an in-line valuation (i.e. relative to the covered E&Cs) is...
-
UPDATE: Citigroup Reiterates Buy Rating, Raises PT for KLA-Tencor
Friday, April 27, 2012 - 10:15am | 117In a company update released earlier today, Citigroup Inc. reiterated its Buy rating for KLA-Tencor Corporation (NASDAQ: KLAC) and slightly raised its price target from $65.00 to $66.00. Citigroup said it reiterated its Buy rating “to reflect its exposure to the foundry/logic driven capex spending...
-
UPDATE: Citigroup Maintains Neutral Rating, Raises PT for Baker Hughes
Wednesday, April 25, 2012 - 12:32pm | 120In a company update released earlier today, Citigroup Inc. maintained its Neutral rating for Baker Hughes Incorporated (NYSE: BHI) and raised its price target from $46.00 to $48.00. Citigroup said in their report “Going forward, the company announced an operational plan to address supply chain...
-
UPDATE: Citigroup Reiterates Neutral Rating, Raises PT for Total System Services
Wednesday, April 25, 2012 - 12:13pm | 120In a company update published earlier today, Citigroup Inc. reiterated its Neutral rating for Total System Services, Inc. (NYSE: TSS) and raised its price target from $20.00 to $23.00. Citigroup said in its report “We believe Durbin helped TSS' direct merchant business in 1Q, while less than...
-
UPDATE: Citigroup Reiterates Buy Rating, $37 PT for Mattel
Monday, April 16, 2012 - 2:46pm | 111In a company update issued earlier today, Citigroup Inc. reiterated its Buy rating and $37 price target for Mattel, Inc. (NASDAQ: MAT). Citigroup went on to say “We were surprised that the company was able to only miss by a penny despite a pretty big miss on shipments (reductions in retail...
-
Study: Citigroup Stock Not Affected By U.S. Treasury Sales
Thursday, July 15, 2010 - 9:23am | 203The sale of shares in Citigroup [NYSE: C] by the U.S. Treasury Department was found to not have had an effect on the value of Citigroup's shares, according to The New York Times. Linus Wilson, a finance professor at University of Louisiana at Lafayette conducted a study showing the opposite, that...
-
Citigroup Ups Price Target on Aegon
Wednesday, May 12, 2010 - 11:28am | 132Shares of Aegon NV (NYSE: AEG) are flat on the session at $6.55 after the company reported earnings that beat Street estimates. Citigroup (NYSE: C) said that the earnings were solid, not blow-out as the number suggests, but that they see plenty of valuation support, particularly in relation to U.S...
-
Jeffries & Company Issues Opinion On "Truth in Lending Act"
Thursday, March 4, 2010 - 10:06am | 232Jeffries & Company analysts Richard B. Shane Jr., Jonathan M. Philpot and Roman Leal wrote an opinion on the "Truth in Lending Act". They said that the proposal balances protecting consumers with credit card issuer's profitability. They were initially concerned that because of the current...
-
Citigroup (C) Long Term Profits "Not Really A Concern"
Friday, January 29, 2010 - 3:11pm | 107During an interview with CNBC on Friday, the Chief Executive of Citigroup Inc. (NYSE: C) said that profitability over the long term "is not really a concern." "On a near-term basis there are some credit concerns, but profitability is not really a concern on a long term basis," Vikram Pandit said. "...